BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INCB161734 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INCB161734\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06179160-2548@assetmemo.bio
DTSTAMP:20261121T005852Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:INCB161734: Phase 1 readout est. (NCT06179160)
DESCRIPTION:INCB161734\, phase 1.\nStudy: A Study to Evaluate INCB161734 in
  Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Muta
 tion\nEstimated primary completion: 1 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/incb161734#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06179160
URL:https://assetmemo.bio/drug/incb161734#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854249-2548@assetmemo.bio
DTSTAMP:20261121T005852Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:INCB161734: Phase 1 readout est. (NCT07854249)
DESCRIPTION:INCB161734\, phase 1.\nStudy: A Study to Evaluate the Pharmacok
 inetics and Safety of INCB161734 in Participants With Impaired Renal Funct
 ion and Participants on Hemodialysis\nEstimated primary completion: 30 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/incb161734#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07854
 249
URL:https://assetmemo.bio/drug/incb161734#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853040-2548@assetmemo.bio
DTSTAMP:20261121T005852Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:INCB161734: Phase 1 readout est. (NCT07853040)
DESCRIPTION:INCB161734\, phase 1.\nStudy: A Study to Evaluate the Pharmacok
 inetics and Safety of INCB161734 in Participants With Hepatic Impairment\n
 Estimated primary completion: 31 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/incb161734#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07853040
URL:https://assetmemo.bio/drug/incb161734#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522073-2548@assetmemo.bio
DTSTAMP:20261121T005852Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:INCB161734: Phase 3 readout est. (NCT07522073)
DESCRIPTION:INCB161734\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStudy
 : A Study to Evaluate Chemotherapy With or Without INCB161734 in Previousl
 y Untreated\, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinom
 a\nEstimated primary completion: 15 September 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/incb161734#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07522073
URL:https://assetmemo.bio/drug/incb161734#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
